
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed o... Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -8.18181818182 | 1.1 | 1.13 | 0.9365 | 42720 | 1.02569914 | CS |
4 | 0.01 | 1 | 1 | 1.18 | 0.78 | 537079 | 0.84573181 | CS |
12 | 0.0879 | 9.53258865633 | 0.9221 | 1.25 | 0.7301 | 219626 | 0.86576991 | CS |
26 | -0.1064 | -9.5306341813 | 1.1164 | 1.78 | 0.7301 | 135367 | 0.95356042 | CS |
52 | 0.08 | 8.60215053763 | 0.93 | 3.23 | 0.63 | 125221 | 1.20113287 | CS |
156 | -4.2 | -80.6142034549 | 5.21 | 5.62 | 0.63 | 94691 | 1.31301397 | CS |
260 | -4.2 | -80.6142034549 | 5.21 | 5.62 | 0.63 | 94691 | 1.31301397 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions